DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
08 2022
Historique:
received: 06 05 2021
accepted: 26 04 2022
pubmed: 8 6 2022
medline: 12 10 2022
entrez: 7 6 2022
Statut: ppublish

Résumé

Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human. We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile systemic erythematosus lupus (jSLE) patients. We measured interferon-stimulated gene (ISG) expression in all patients. We performed a systematic review of all published cases available from its first description in 2011 to March 24 We identified five new patients carrying biallelic DNASE1L3 pathogenic variations, including three previously unreported mutations. Contrary to canonical type I interferonopathies, we noticed a transient increase of ISGs in blood, which returned to normal with disease remission. Disease in one patient was characterized by lupus nephritis and skin lesions, while four others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented also with early-onset inflammatory bowel disease. Reviewing previous reports, we identified 35 additional patients with DNASE1L3 deficiency which was associated with a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Lung lesions were reported in 6/35 patients. DNASE1L3 deficiencies are associated with a broad phenotype including frequently lupus nephritis and hypocomplementemic urticarial vasculitis with positive ANCA and rarely, alveolar hemorrhages and inflammatory bowel disease. This report shows that interferon production is transient contrary to anomalies of intracellular DNA sensing and signaling observed in Aicardi-Goutières syndrome or STING-associated vasculitis in infancy (SAVI).

Sections du résumé

BACKGROUND
Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans.
OBJECTIVES
To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human.
METHODS
We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile systemic erythematosus lupus (jSLE) patients. We measured interferon-stimulated gene (ISG) expression in all patients. We performed a systematic review of all published cases available from its first description in 2011 to March 24
RESULTS
We identified five new patients carrying biallelic DNASE1L3 pathogenic variations, including three previously unreported mutations. Contrary to canonical type I interferonopathies, we noticed a transient increase of ISGs in blood, which returned to normal with disease remission. Disease in one patient was characterized by lupus nephritis and skin lesions, while four others exhibited hypocomplementemic urticarial vasculitis syndrome. The fourth patient presented also with early-onset inflammatory bowel disease. Reviewing previous reports, we identified 35 additional patients with DNASE1L3 deficiency which was associated with a significant risk of lupus nephritis and a poor outcome together with the presence of anti-neutrophil cytoplasmic antibodies (ANCA). Lung lesions were reported in 6/35 patients.
CONCLUSIONS
DNASE1L3 deficiencies are associated with a broad phenotype including frequently lupus nephritis and hypocomplementemic urticarial vasculitis with positive ANCA and rarely, alveolar hemorrhages and inflammatory bowel disease. This report shows that interferon production is transient contrary to anomalies of intracellular DNA sensing and signaling observed in Aicardi-Goutières syndrome or STING-associated vasculitis in infancy (SAVI).

Identifiants

pubmed: 35670985
doi: 10.1007/s10875-022-01287-5
pii: 10.1007/s10875-022-01287-5
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Chromatin 0
Interferon Type I 0
DNA 9007-49-2
Interferons 9008-11-1
DNASE1L3 protein, human EC 3.1.-
Endodeoxyribonucleases EC 3.1.-

Types de publication

Journal Article Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1310-1320

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-10-IAHU-01
Organisme : Agence Nationale de la Recherche
ID : ANR-21-CE17-0064-01

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Belot A, Rice GI, Omarjee SO, Rouchon Q, Smith EMD, Moreews M, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol [Internet]. 2020 [cited 2020 Jan 16];0. Available from: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30142-0/abstract .
Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J. 2012;10:21.
doi: 10.1186/1546-0096-10-21
Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: dissecting heterogeneity. Autoimmun Rev. 2019;18:102361.
doi: 10.1016/j.autrev.2019.102361
Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43:127–31.
doi: 10.1038/ng.748
An J, Briggs TA, Dumax-Vorzet A, Alarcón-Riquelme ME, Belot A, Beresford M, et al. Tartrate-resistant acid phosphatase deficiency in the predisposition to systemic lupus erythematosus. Arthritis Rheumatol Hoboken NJ. 2017;69:131–42.
doi: 10.1002/art.39810
Crow YJ. Lupus: how much “complexity” is really (just) genetic heterogeneity? Arthritis Rheum. 2011;63:3661–4.
doi: 10.1002/art.30603
Belot A, Kasher PR, Trotter EW, Foray A-P, Debaud A-L, Rice GI, et al. Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65:2161–71.
doi: 10.1002/art.38008
Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43:1186–8.
doi: 10.1038/ng.975
Özçakar ZB, Foster J, Diaz-Horta O, Kasapcopur O, Fan Y-S, Yalçınkaya F, et al. DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 2013;65:2183–9.
doi: 10.1002/art.38010
Carbonella A, Mancano G, Gremese E, Alkuraya FS, Patel N, Gurrieri F, et al. An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus. 2017;26:768–72.
doi: 10.1177/0961203316676382
Batu ED, Koşukcu C, Taşkıran E, Sahin S, Akman S, Sözeri B, et al. Whole exome sequencing in early-onset systemic lupus erythematosus. J Rheumatol. 2018;45:1671–9.
doi: 10.3899/jrheum.171358
Bruschi M, Bonanni A, Petretto A, Vaglio A, Pratesi F, Santucci L, et al. Neutrophil extracellular traps (NETs) profiles in patients with incident SLE and lupus nephritis. J Rheumatol. 2020;47:377–86.   
Ranalli M, Passarelli C, Messia V, Pardeo M, Sacco E, Insalaco A, et al. Fri0554 Dnase1l3 variant in hypocomplementemic urticarial vasculitis syndrome identifies a different clinical phenotype. Ann Rheum Dis. BMJ Publishing Group Ltd; 2019;78:972–3.
Yıldırım DG, Bakkaloğlu SA. Monogenic lupus caused by mutations in DNASE1L3: a rare cause of systemic lupus erythematosus in children. Scand J Immunol. 2022;e13162.
Kisla Ekinci RM, Balci S, Ozcan D, Atmis B, Bisgin A. Monogenic lupus due to DNASE1L3 deficiency in a pediatric patient with urticarial rash, hypocomplementemia, pulmonary hemorrhage, and immune-complex glomerulonephritis. Eur J Med Genet. 2021;64:104262.
doi: 10.1016/j.ejmg.2021.104262
Paç Kisaarslan A, Witzel M, Unal E, Rohlfs M, Akyildiz B, Dogan ME, et al. Refractory and fatal presentation of severe autoimmune hemolytic anemia in a child with the DNASE1L3 mutation complicated with an additional DOCK8 variant. J Pediatr Hematol Oncol. 2021;43:e452–6.
doi: 10.1097/MPH.0000000000001780
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
doi: 10.1056/NEJMra1100359
Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30.
doi: 10.1038/nrrheum.2016.186
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711–23.
doi: 10.1084/jem.20021553
Crow YJ. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr Opin Immunol. 2015;32C:7–12.
doi: 10.1016/j.coi.2014.10.005
Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med. 2017;68:297–315.
doi: 10.1146/annurev-med-050715-104506
Lin B, Goldbach-Mansky R. Pathogenic insights from genetic causes of autoinflammatory inflammasomopathies and interferonopathies. J Allergy Clin Immunol. 2022;149:819–32.
doi: 10.1016/j.jaci.2021.10.027
Aicardi J, Goutières F. Systemic lupus erythematosus or Aicardi-Goutières syndrome? Neuropediatrics. 2000;31:113.
doi: 10.1055/s-2000-7533
Rice GI, Forte GMA, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12:1159–69.
doi: 10.1016/S1474-4422(13)70258-8
Sisirak V, Sally B, D’Agati V, Martinez-Ortiz W, Özçakar ZB, David J, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166:88–101.
doi: 10.1016/j.cell.2016.05.034
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med Off J Am Coll Med Genet. 2015;17:405–24.
Weill O, Decramer S, Malcus C, Kassai B, Rouvet I, Ginhoux T, et al. Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. Joint Bone Spine. 2017;84:589–93.
Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998;16:541–6.
pubmed: 9779300
Rice GI, Forte G, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR a case-control study. Lancet Neurol. 2013;12:1159–69.
doi: 10.1016/S1474-4422(13)70258-8
Rodero MP, Tesser A, Bartok E, Rice GI, Della Mina E, Depp M, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;19;8:2176.
de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020;130:1669–82.
doi: 10.1172/JCI129301
Napirei M, Ludwig S, Mezrhab J, Klöckl T, Mannherz HG. Murine serum nucleases – contrasting effects of plasmin and heparin on the activities of DNase1 and DNase1-like 3 (DNase1l3). FEBS J. 2009;276:1059–73.
doi: 10.1111/j.1742-4658.2008.06849.x

Auteurs

Maud Tusseau (M)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Genetics Department, Lyon University Hospital, Lyon, France.

Ema Lovšin (E)

University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia.

Charlotte Samaille (C)

Nephrologie Pediatrique, Hôpital Jeanne de Flandre, CHU Lille, Lille, France.

Rémi Pescarmona (R)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.

Anne-Laure Mathieu (AL)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.

Maria-Cristina Maggio (MC)

University Department PROMISE "G. D'Alessandro", University of Palermo, Palermo, Italy.

Velma Selmanović (V)

Children's Hospital, University Clinical Center , Sarajevo, Bosnia and Herzegovina.

Marusa Debeljak (M)

University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia.

Angelique Dachy (A)

Nephrologie Pediatrique, Hôpital Jeanne de Flandre, CHU Lille, Lille, France.

Gregor Novljan (G)

Pediatric Nephrology Department, Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Alexandre Janin (A)

Cardiogenetics Laboratory, Biochemistry and Molecular Biology Department, Lyon University Hospital, Lyon, France.
NeuroMyoGene Institute, Lyon 1 University, CNRS UMR 5510, INSERM U1217, Lyon, France.

Louis Januel (L)

NeuroMyoGene Institute, Lyon 1 University, CNRS UMR 5510, INSERM U1217, Lyon, France.

Jean-Baptiste Gibier (JB)

University Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France.

Emilie Chopin (E)

Centre de Biotechnologie Cellulaire Et Biothèque, Hospices Civils de Lyon, Bron, France.

Isabelle Rouvet (I)

Centre de Biotechnologie Cellulaire Et Biothèque, Hospices Civils de Lyon, Bron, France.

David Goncalves (D)

Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.

Nicole Fabien (N)

Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.

Gillian I Rice (GI)

Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Gaétan Lesca (G)

Genetics Department, Lyon University Hospital, Lyon, France.

Audrey Labalme (A)

Genetics Department, Lyon University Hospital, Lyon, France.

Paola Romagnani (P)

Nephrology Unit, Anna Meyer Children Hospital and University of Florence, University of Florence, Florence, Italy.

Thierry Walzer (T)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.

Sebastien Viel (S)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.

Magali Perret (M)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Benite, France.

Yanick J Crow (YJ)

Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Université de Paris, Paris, France.
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Tadej Avčin (T)

University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia.

Rolando Cimaz (R)

ASST G. Pini, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy.

Alexandre Belot (A)

The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France. alexandre.belot@chu-lyon.fr.
National Referee Centre for Rheumatic and Autoimmune Diseases in Children, RAISE, Paris and Lyon, France. alexandre.belot@chu-lyon.fr.
Pediatric Nephrology, Rheumatology, Dermatology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Bd Pinel, 68677, Bron Cedex, France. alexandre.belot@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH